Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States.
Saved in:
| Title: | Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States. |
|---|---|
| Authors: | Shah HA; GSK, London, UK. hiral.a.shah@gsk.com.; Neisseria Portfolio, Value Evidence & Outcomes Team, 90 Great West Road, Brentford, TW8 9GS, UK. hiral.a.shah@gsk.com., Jutlla G; GSK, London, UK., Herrera-Restrepo O; GSK, Philadelphia, PA, USA., Graham J; RTI Health Solutions, Research Triangle Park, NC, USA., Hicks KA; RTI Health Solutions, Research Triangle Park, NC, USA., Carrico J; GSK, Durham, NC, USA., Grace M; RTI Health Solutions, Research Triangle Park, NC, USA., Clements DE; GSK, Philadelphia, PA, USA., Burman C; GSK, Philadelphia, PA, USA., Sohn WY; GSK, Rockville, MD, USA., Kuylen E; GSK, Wavre, Belgium., Begum S; GSK, London, UK., Kocaata Z; GSK, Wavre, Belgium. |
| Source: | PharmacoEconomics [Pharmacoeconomics] 2025 Mar; Vol. 43 (3), pp. 311-329. Date of Electronic Publication: 2024 Nov 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-2027 |
|---|---|
| DOI: | 10.1007/s40273-024-01439-y |
